N/A N=94 Simultaneous TransPRK and Corneal Collagen Cross-Linking
Keratoconus
Primary: Change in LogMAR Corrected Distance Visual Acuity (CDVA) — -0.13; -0.05 LogMAR CDVA — p=0.03
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=239 Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
Progressive Keratoconus
Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004
Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
N/A N=12 Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Keratoconus
Primary: Number of Participants With Normal Vision — 8 Participants
Phase 2 N=18 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
Osteosarcoma
Primary: Response Rate — 0 percentage of participants
N/A N=3 Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
Primary Progressive Aphasia
Primary: Connectivity Measures of the Left TGd, 55b, and STV Parcellations at Baseline and Post-treatment — -.06; .03; -.01 correlation
Phase 2 N=36 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
N/A N=15 G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis
Progressive Multiple Sclerosis
Primary: Comfortable Walking Speed — .45; .60; .52; .67 meters per second — p=.405
Phase 2 N=85 Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Primary Progressive Multiple Sclerosis
Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…
N/A N=30 Transepithelial Corneal Cross-linking Using Iontophoresis
Progressive Keratoconus
Primary: K-max — -0.52; -0.82 Diopters (D) — p=<0.05
Phase 2 N=255 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Multiple Sclerosis, Primary Progressive · Multiple Sclerosis, Secondary Progressive
Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04
Phase 2 N=11 Everolimus for Children With Recurrent or Progressive Ependymoma
Recurrent Childhood Ependymoma
Primary: Objective Response Rate (Complete Response Rate and Partial Response Rate) Following Treatment With Everolimus for Children With Recurrent or Progressive Ependymomas…
N/A N=12 Progressive Strength Training in Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Strength — 0.39 kilograms
Phase 3 N=81 A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) — -191.89; -85.32 Milliliter/year